Research

Mixed

The gut-microbiome derived metabolite 3-(4-hydroxyphenyl)lactate is significantly associated with hepatic fibrosis and steatosis in NAFLD, sharing a significant genetic determination with these liver conditions.

This research highlights that a specific gut-derived metabolite, 3-(4-hydroxyphenyl)lactate, is linked to liver scarring (fibrosis) and fat accumulation in NAFLD. While this is a biomarker finding rather than a direct treatment, it suggests that modulating gut microbiome composition or function could be a future therapeutic target for managing NAFLD progression. Patients should focus on general gut health through fiber-rich diets and avoiding unnecessary antibiotics, as these support a healthy microbiome, though specific 'probiotic' prescriptions for this metabolite are not yet established.

GoodSupportsHIGH confidence
Among them, only one microbial metabolite, 3-(4-hydroxyphenyl)lactate, remained consistent and statistically significantly associated with liver fibrosis in the discovery and validation cohort... The share genetic determination of 3-(4-hydroxyphenyl)lactate with hepatic steatosis was RG:0.57... and with fibrosis was RG:0.54...
Cyrielle Caussy et al. · Hepatology · 2018

Why this rating

The study uses a robust twin/family design for heritability, a large discovery cohort, and an independent biopsy-proven validation cohort, providing strong observational evidence, though it is not an interventional trial.

Source

Link between gut‐microbiome derived metabolite and shared gene‐effects with hepatic steatosis and fibrosis in NAFLD

Cyrielle Caussy et al. · Hepatology · 2018

DOI 10.1002/hep.29892

cross_sectional · n=312Cited 200×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →